- Home
- » Tags
- » Serum Institute of India
Top View
- V3P: Region Fact Sheet SEAR
- “Pandemic Hole”? a Narrative Review on SARS-Cov-2 Vaccination: from Animal Models to Human Immunization
- 2 Made in India Vaccines.Cdr
- Quality Evaluation of Clinical Consistency Lots of Menfive, a Pentavalent (A,C,W,X,Y) Meningococcal Serogroup Conjugate Vaccine
- Pneumococcal Conjugate Vaccine
- E-Samvaad October, 2020 INDIAN COUNCIL of MEDICAL RESEARCH
- Covid-19: India Is at Centre of Global Vaccine Manufacturing
- Is Target of 216.6 Cr Jabs ‚Mission Impossible™ for India?
- Fact Sheet for Vaccine Recipient
- COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System As a Potential Vaccine Platform
- COVID-19 Vaccines: a Review of the Safety and Efficacy of Current
- Introduction of Pentavalent Vaccine in India
- Bovine Rotavirus Pentavalent Vaccine Development in India
- COVID-19 Vaccine: the Fight Against SARS-Cov-2 Infection Saima Syeda and Anju Shrivastava* Department of Zoology, University of Delhi, Delhi-110007, India
- Bacille Calmette-Guérin (BCG) Vaccine and the COVID-19 Pandemic: Responsible Stewardship Is Needed
- Vaccine Development for COVID-19
- Expression of Interest on Supply of COVID-19 Vaccines on Behalf of The
- เอกสารกำกับยาภาษาอังกฤษ Hepatitis B Vaccine (Rdna)
- Indian Companies Find US Partners for COVID-19 Vaccines Indian Companies Find US Partners for COVID-19 Vaccines
- A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials
- Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with Cpg 1018
- Status of COVID-19 Vaccines Within WHO EUL/PQ Evaluation Process
- Effectiveness of Booster BCG Vaccination in Preventing Covid-19 Infection
- Covid-19 Vaccine Shortages
- Update on TB Vaccine Pipeline
- SCHOTT and Serum Institute of India Announce Joint Venture for Pharmaceutical Packaging
- Responsive COVID-19 Vaccines for Recovery Project Under the Asia Pacific Vaccine Access Facility (RRP INO 54425-001)
- V3P: Region Fact Sheet AMR
- Hope for Less Than 50 Cents a Dose: a Revolutionary Model For
- COVID-19 Vaccine Chadox1-S [Recombinant] Developed by Oxford University and Astrazeneca
- COVID-19 Vaccine Chadox1-S [Recombinant] Developed by Oxford University and Astrazeneca Manufacturers2: • SK Bioscience Co
- Protection Against SARS-Cov-2 by BCG Vaccination Is Not Supported
- ORF Specialreport 143 Vacci
- Frequently Asked Questions About COVID-19 Vaccines
- Serum Institute of India Pvt. Ltd. Ticker: - HQ: Pune, India Employees: Unknown Index Performance by Research Area
- Updates on COVID-19 Vaccine Development and India's Roles in Vaccine Preparation
- (DCGI) on Restricted Emergency Approval of COVID-19 Virus Vaccine
- Pdf | 751.85 Kb
- Industry Partnerships on COVID-19 Vaccines, Therapeutics and Diagnostics
- Enabling Equitable Access to COVID-19 Vaccines: Summary of Equitable Access Provisions in CEPI’S COVID-19 Vaccine Development Agreements
- 21-12 How COVID-19 Vaccine Supply Chains Emerged in the Midst of a Pandemic
- 19 Vaccine Doses for India and Low- and Middle-Income Countries in 2021
- Dtphbhib Insert
- CTRI Trial Data
- Name and Manufacturer Platform Age Indications Dosages Description Storage and Shelf-Life Temperature Approval Efficacy
- Sabin Vaccine Report
- Dtwp-Hepb-Hib Vaccine Available in a Compact, Pre-Filled Auto-Disable Injection Technology (Cpad)
- Bcg New Rev. 260614
- In the High Court of Judicature at Bombay Civil Appellate Jurisdiction
- Pentavalent Vaccine (Dtwp-Hepb-Hib): Market & Supply Update May 2017
- Ra Capital's Covid-19 Map
- COVISHIELD™ Vaccine, Then the Second Dose Should Be Administered Between 4 to 6 Weeks After the First Dose
- Weekly Operational Update on COVID-19